Skip to main content

Akero Therapeutics, Inc. (AKRO)

NASDAQ: AKRO · Delayed Price · USD
21.05
1.00 (4.99%)
At close: Dec 7, 2021 4:00 PM
21.30
0.25 (1.19%)
After-hours:Dec 7, 2021 4:46 PM EST
Market Cap734.40M
Revenue (ttm)n/a
Net Income (ttm)-98.06M
Shares Out34.89M
EPS (ttm)-2.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume172,430
Open20.31
Previous Close20.05
Day's Range20.31 - 21.48
52-Week Range17.66 - 34.87
Beta0.50
AnalystsStrong Buy
Price Target47.50 (+125.7%)
Earnings DateNov 11, 2021

About AKRO

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patient...

IndustryBiotechnology
IPO DateJun 20, 2019
Employees31
Stock ExchangeNASDAQ
Ticker SymbolAKRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is 47.50, which is an increase of 125.65% from the latest price.

Price Target
$47.50
(125.65% upside)
Analyst Consensus: Strong Buy

News

Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference

SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseas...

1 week ago - GlobeNewsWire

Wall Street Analysts Think Akero Therapeutics, Inc. (AKRO) Could Surge 92%: Read This Before Placing a Bet

The mean of analysts' price targets for Akero Therapeutics, Inc. (AKRO) points to a 91.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

2 weeks ago - Zacks Investment Research

Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological I...

Most EFX-treated patients with end-of-treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks

3 weeks ago - GlobeNewsWire

Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic ...

3 weeks ago - GlobeNewsWire

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metaboli...

4 weeks ago - GlobeNewsWire

Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH

SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohe...

1 month ago - GlobeNewsWire

Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic ...

2 months ago - GlobeNewsWire

Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic ...

3 months ago - GlobeNewsWire

Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic ...

4 months ago - GlobeNewsWire

Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment

Akero Therapeutics Inc (NASDAQ: AKRO) has announced full results of the main portion of its Phase 2a BALANCED trial of efruxifermin (EFX) in NASH patients with F1-F3 fibrosis have been published in Natu...

4 months ago - Benzinga

Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fi...

Efruxifermin (EFX) also improved markers of liver injury, inflammation, lipoproteins, and glycemic control Efruxifermin (EFX) also improved markers of liver injury, inflammation, lipoproteins, and glyce...

4 months ago - GlobeNewsWire

Akero Therapeutics Presents at the American Diabetes Association's 81st Scientific Sessions, Demonstrating that Impro...

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic ...

5 months ago - GlobeNewsWire

Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients

Akero Therapeutics Inc (NASDAQ: AKRO) has announced additional analyses from its Phase 2a BALANCED study of efruxifermin (EFX) in non-alcoholic steatohepatitis (NASH) patients with F1-F3 fibrosis. Data ...

5 months ago - Benzinga

Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Subs...

Analyses also Show that Combining a Threshold for ALT Reduction of ≥17 U/L with Normalization of Liver Fat Improves Predictive Power for Resolution of NASH with 1-Stage Improvement of Fibrosis Analyses ...

5 months ago - GlobeNewsWire

Can Akero Therapeutics (AKRO) Run Higher on Strong Earnings Estimate Revisions?

Akero Therapeutics (AKRO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

5 months ago - Zacks Investment Research

Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference

SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis...

6 months ago - GlobeNewsWire

Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic s...

6 months ago - GlobeNewsWire

Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C

-- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of EFX patients (3 of 12) showed NASH resolution --

8 months ago - GlobeNewsWire

Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients

SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...

8 months ago - GlobeNewsWire

Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...

8 months ago - GlobeNewsWire

Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (N...

9 months ago - PRNewsWire

Akero Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NA...

11 months ago - Business Wire

Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steat...

1 year ago - Business Wire

Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Fou...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced the presentation of additional data analysis from the Phase 2a BALANCED study at the Presidential Or...

1 year ago - Business Wire

Akero Therapeutics Reports Third Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines design...

1 year ago - PRNewsWire